Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
The effects of Rolipram, a new phosphodiesterase inhibitor, were assessed in a double-blind trial versus placebo in 10 patients with Parkinson's disease already under treatment. Contrary to previous findings with specific phosphodiesterase inhibitors, with Rolipram (at the dose of 3 mg per day), no significant deterioration of the therapeutic action of dopamine agonist Lisuride was noted.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000368:Aged; D006801:Humans; D008090:Lisuride / Q000627:therapeutic use; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D011954:Receptors, Dopamine / Q000187:drug effects; D020889:Rolipram
D011760:Pyrrolidinones; D011954:Receptors, Dopamine; D008090:Lisuride; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D020889:Rolipram